Hypera SA
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamm… Read more
Hypera SA (HYPMY) - Total Liabilities
Latest total liabilities as of September 2025: $16.27 Billion USD
Based on the latest financial reports, Hypera SA (HYPMY) has total liabilities worth $16.27 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hypera SA - Total Liabilities Trend (2005–2024)
This chart illustrates how Hypera SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hypera SA Competitors by Total Liabilities
The table below lists competitors of Hypera SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Distribution Solutions Group Inc
NASDAQ:DSGR
|
USA | $1.11 Billion |
|
CPT Technology Group Co Ltd
SHE:000536
|
China | CN¥4.81 Billion |
|
Norconsult ASA
OL:NORCO
|
Norway | Nkr4.47 Billion |
|
Sunonwealth Electric Machine Industry Co Ltd
TW:2421
|
Taiwan | NT$7.31 Billion |
|
Nexus AG
F:NXU
|
Germany | €180.79 Million |
|
Fielmann Aktiengesellschaft
PINK:FLMNF
|
USA | $-913.14 Million |
|
Caihong Display Devices Co Ltd
SHG:600707
|
China | CN¥18.63 Billion |
|
Safety Insurance Group Inc
NASDAQ:SAFT
|
USA | $1.55 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Hypera SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hypera SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hypera SA (2005–2024)
The table below shows the annual total liabilities of Hypera SA from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $12.46 Billion | -4.11% |
| 2023-12-31 | $12.99 Billion | -0.83% |
| 2022-12-31 | $13.10 Billion | +31.21% |
| 2021-12-31 | $9.98 Billion | +24.66% |
| 2020-12-31 | $8.01 Billion | +149.55% |
| 2019-12-31 | $3.21 Billion | +40.19% |
| 2018-12-31 | $2.29 Billion | -4.32% |
| 2017-12-31 | $2.39 Billion | -10.55% |
| 2016-12-31 | $2.67 Billion | -65.68% |
| 2015-12-31 | $7.79 Billion | +21.54% |
| 2014-12-31 | $6.41 Billion | +18.22% |
| 2013-12-31 | $5.42 Billion | -6.30% |
| 2012-12-31 | $5.79 Billion | -13.34% |
| 2011-12-31 | $6.68 Billion | +35.54% |
| 2010-12-31 | $4.93 Billion | +72.90% |
| 2009-12-31 | $2.85 Billion | +72.86% |
| 2008-12-31 | $1.65 Billion | +29.03% |
| 2007-12-31 | $1.28 Billion | +353.43% |
| 2006-12-31 | $281.83 Million | +29.69% |
| 2005-12-31 | $217.30 Million | -- |